Tauriga Sciences Is Poised To Establish Itself In The Marijuana Industry (Part One)
April 17th, 2014
After an “unusual series of problems,” Tauriga Sciences (OTC: TAUG) was able to “reinvent themselves” with the help of newly-appointed CEO Dr. Stella Sung.
When an exclusive license agreement went wrong, Immunovative Inc. (Tauriga’s predecessor company) had a very uncertain future.
Immunovative filed a lawsuit against Immunovative Therapies Ltd. regarding the termination of their exclusive license agreement, but after settling outside of court, Immunovative only received a nine percent equity stake in the Israeli firm.
Without that exclusive license, which was the company’s key asset, Immunovative was left to “rise from the ashes.” Thus,Tauriga was born.
The current company exists with the goal of creating a diversified portfolio of assets, that include licensing agreements and acquisitions of companies that utilize life science technology.
According to Dr.Sung, the company has and will continue, to pursue company acquisitions that have products with a “clear path to commercialization,” and have to chance to compete in a market with reduced FDA regulatory risks. That is where marijuana comes into play.
Traditionally, bio-therapeutics have vast regulatory risks, which is why Dr.Sung wants to “apply interesting life science technology to markets with huge applicability,” while avoiding the need for FDA approval.
Marijuana-based products are not yet regulated by the FDA, with makes cannabis the ideal component for Sung and the Tauriga team.
Honeywell LLC Acquisition
On March 11th, 2014, Tauriga announced the acquisition of California’s leading manufacturer of topical medicinal cannabis products, Honeywood LLC. This acquisition launched Tauriga into the marijuana space, using Honeywood’s Doc Green’s brand of topical creams as an entry point to the canna-business space.
Doc Green’s produces cannabis oil infused creams that are designed to alleviate pain while providing no psychoactive effects. Doc Green creams were the first professionally packaged and widely distributed cannabis product on the California market, and are found in hundreds of dispensaries.
Dr. Sung told Benzinga her comments are not medical claims, but noted that “it has been suggested that cannabis, and this specific formulation, really interacts with the CB2 receptors associated with pain and inflammation, and we have a lot of testimonials where people say it helped them.”
Doc Green’s target audience is the elderly population, as many “are already taking a lot of oral medications and don’t want to take any more due to the fear of sides effects from drug-drug interactions, but do suffer from pain and discomfort. “
Dr. Sung also stressed the importance of cost efficiency, noting that “other prescription analgesic topical creams are not covered under Medicare Part D, so they are super expensive” (a 4 ounce bottle of Vanilla Scented Doc Greens cream is $20.00).
Further development in the cannabis space for Tauriga seems evident, but Dr.Sung is not sure if they will expand under the Doc Green’s brand, or if they will make further acquisitions.
“We are committed to our current legitimate cannabis business as an entry point,” she said, “and we believe that cannabis has a lot of benefits. Overall, the cannabis related area is very, very promising.”
Dr. Lawrence A. May MD joined the Tauriga team in April of 2013, and brings a wealth of experience in the life science space. Dr. May served as the executive vice president for medical and scientific affairs for Herbalife international, and Dr.Sung is confident he will be a huge contributor to future cannabis related projects.
“ I think his background is perfect for developing supplements related to cannabis effects [including] memory and cognitive issues, appetite, and depression,” she said.
Tauriga hopes to develop a better presence by placing their products in dispensaries, but does not want to limit themselves, and will use other distribution channels as well.
This is part one of a two-part interview with Tauriga Sciences CEO Dr.Stella Sung
To learn more about the expanding cannabis financial industry, check out the 420 Investor on Marketfy.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.